A clinical trial led by researchers from Hospital Clínic de Barcelona, the August Pi i Sunyer Biomedical Research Institute ...
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight The Treg cell-based therapies clinical trial analysis ...
Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile --The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet ...
Amtagvi approval with FY25 sales significantly lower than initial guidance and significant share dilution. Learn more about ...
The funding is anticipated to support Angel Pharma’s ongoing Phase 1b/2 trial of soquelitinib for atopic dermatitis and a new Phase 2 trial of soquelitinib for asthma. Angel Pharma anticipates that it ...
The myasthenia gravis clinical trial analysis report delivers important insights into ongoing research of 30+ pipeline ...
Inhaled microplastics can stay in lungs for weeks and trigger allergies - Studies have shown that in tissues where they ...
First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ...
Russian scientists have developed a mathematical model to study the malfunction of the protective system in autoimmune ...
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Iovance is investigating Amtagvi in frontline advanced melanoma in the Phase 3 trial, TILVANCE-301 (NCT05727904), as well as in additional solid tumor types. About Iovance Biotherapeutics, Inc.
On June 4, 2026, CNBC reported that global biopharma M&A is on track for its strongest year since the pre-pandemic peak seven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results